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Abstract
Background: The EP1 receptor for the prostanoid PGE2 is a G-protein coupled receptor that has
been shown to contribute to excitotoxic neuronal death. In this study we examined the influence
of non-neuronal cells on neuroprotective properties of EP1 receptor antagonists (Ono 8711 and
SC 51089).
Methods: Primary neuronal cultures systems with or without non-neuronal cells were used to
examine how the neuroprotective properties of EP1 antagonists were influenced by non-neuronal
cells. The influence of astrocytes or microglia were individually tested in excitotoxicity assays using
a co-culture system with these cells grown on permeable transwell inserts above the neuronal-
enriched cultures. The influence of microglia on PGE2 synthesis and EP1 receptor expression was
examined.
Results: EP1 antagonists were neuroprotective in neuronal-enriched cultures (> 90% neurons) but
not in mixed cultures (30% neurons plus other non-neuronal cells). Co-cultures of microglia on
permeable transwell inserts above neuronal-enriched cultures blocked neuroprotection by EP1
antagonists. Incubation of microglia with neuronal-enriched cultures for 48 hours prior to NMDA
challenge was sufficient to block neuroprotection by EP1 antagonists. The loss of neuroprotection
by EP1 antagonists was accompanied by a decrease of neuronal EP1 expression in the nucleus in
cultures with microglia present.
Conclusion: These findings demonstrate microglial modulation of neuronal excitotoxicity through
interaction with the EP1 receptor and may have important implications in vivo where microglia are
associated with neuronal injury.
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Background
Cyclooxygenase-2 (COX-2), the enzyme that catalyzes the
rate limiting step in the synthesis of prostanoids, contrib-
utes to neuronal death. Inhibitors of COX, termed non-
steroidal anti-inflammatory drugs (NSAIDs) [1], can pro-
tect neurons following an assault with toxic stimuli that
promote excitotoxic death; both in vitro [2,3] and in vivo
[4-7]. COX-2 knockout mice are also less susceptible to
excitotoxicity following exposure to the glutamate recep-
tor agonist N-methyl D-aspartate (NMDA) [8]. Therefore,
a loss of COX-2 activity either by inhibition of the enzyme
or loss of expression is associated with increased neuronal
viability. Conversely, increased COX-2 activity appears to
augment neuronal death. The increased COX-2 expression
in neurons observed in vivo in animal models of stroke
[4], following stimulation with the glutamate receptor
agonist kainic acid [6], and in vitro following NMDA
stimulation [2,3] is coincident with loss of neurons. Con-
stitutive expression of COX-2 in neurons at high amounts
in transgenic mice results in a greater loss of neurons in
stroke models [9] and age-associated loss of neurons [10].
In addition, constitutive COX-2 expression renders neu-
rons more susceptible to NMDA-stimulated death [11].
There are two COX genes, COX-1 and COX-2 [1]. COX
catalyzes the initial steps in the conversion of arachidonic
acid (AA) to one of the five prostanoids, prostacyclin
(PGI2), thromboxane (TxA2), prostaglandin D2 (PGD2),
prostaglandin F2α (PGF2α) and prostaglandin E2 (PGE2)
[1,12]. In addition to the generation of prostanoids, reac-
tive oxygen species (ROS) are also generated by COX-2 in
the reaction of prostanoids [1]. It was demonstrated that
the COX-2-generated prostanoids (and not ROS), are the
major contributors by COX-2 towards excitotoxicity fol-
lowing administration of NMDA to animals [13].
Each of the prostanoids synthesized by COX activates at
least one specific prostanoid receptor. These receptors are
coupled to G-proteins and are designated IP (for PGI2),
TP (for TXA2), DP1 or DP2 (for PGD2), FP (for PGF2α)
and EP1-4 (for PGE2) [12]. Recent investigations have
focused on understanding how activation of specific pros-
tanoids affects neuronal viability. In our earlier studies we
identified that PGF2α and PGE2 were made in primary
neuronal cortical cultures in response to stimulation with
NMDA [3,14]. An analog of PGE2, 17-phenol trinor PGE2
(17-pt-PGE2), but not PGF2α, could reverse the neuro-
protective effect of a COX-2-specific inhibitor in vitro [3]
and in vivo [13] following NMDA administration. These
studies indicate that PGE2 production by COX-2 can con-
tribute to the deleterious actions of COX-2 in NMDA-
mediated excitotoxicity of neurons. However, in vitro
studies investigating the role of PGE2 and its analogs have
yielded contradictory results. PGE2 or its analogs have
been reported to both increase neuronal survival follow-
ing NMDA stimulation [15-19] and in some cases be neu-
rotoxic [20,21]. These opposing effects or PGE2 on
neuronal viability are due to activation of specific EP
receptors that exert either pro survival or pro death effects.
In general, activation of EP1 contributes to neuronal
death [21-24], while activation of EP2 [17-19] and EP4
[24] promote neuroprotection. EP1 has been shown to
contribute to NMDA-mediated neuronal death in vivo
[24]. Decreased EP1 activation by a pharmacologic antag-
onist or genetic knockout of the EP1 receptor decreased
NMDA-stimulated neuronal death, whereas a specific EP1
receptor agonist augmented death [22-24].
Significant progress has been made in understanding how
prostanoids contribute to neuronal death [25]. EP1 recep-
tor activation in neurons has been linked to two different
intracellular mechanisms tied to excitotoxic cell death.
EP1 receptor activation was initially shown to impair the
Na+-Ca2+  exchanger (NCX) which subsequently causes
greater increases in intracellular calcium leading to neuro-
nal death [23]. More recently, EP1 receptor activation has
been linked to the AKT signaling pathway that affects neu-
ronal viability [26].
However, the interaction of EP1 with other cell types in
the central nervous system (CNS) is not well understood.
In this study, we examined whether inhibition of neuro-
nal EP1 contributes to neuronal viability in primary cul-
tures with differing compositions of non neuronal CNS
cells. We investigated the neuroprotective properties of
two specific EP1 receptor antagonists, Ono 8711 [27] and
SC51089 [28] along with a COX-2 inhibitor NS398. This
study demonstrates that the presence of microglia in cul-
ture can offset the neuroprotective effects of EP1 antago-
nists. Our findings have important implications to
conditions where microglia may accumulate following
neuronal injury and potentially limit neuroprotection
conferred by EP1 antagonists.
Methods
Reagents and antibodies
Ono 8711 was generously provided by Takayuki Maru-
yama Ph.D., Ono Pharmaceutical Company, (Osaka,
Japan). N-[2-(cyclohexyloxy)-4-nitrophenyl]-meth-
anesulfonamide (NS398) was obtained from Cayman
Chemical Company, (Ann Arbor MI). SC51089 was
obtained from Biomol, (Plymouth Meeting, PA). NMDA,
MK801 and Arabinose cytosine (AraC) were obtained
from Sigma Chemical Company (St. Louis, MO). Tissue
culture media minimum essential media (MEM) was
obtained from Sigma Chemical Company (St. Louis,
MO), glutamine and trypsin were from Gibco Life Sci-
ences, Invitrogen (Carlsbad, CA). Serum (defined fetal
bovine serum and defined horse serum) was purchased
from Hyclone (Logan, UT). Primary antibodies used inJournal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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this study were, mouse monoclonal anti microtubule
associated protein (MAP)-2 (BD Pharmingen, San Diego,
CA), rabbit polyclonal EP1 (Cayman Chemical Com-
pany), rat monoclonal CD11b (Abcam, Cambridge, MA),
rat monoclonal anti glial fibrillary acidic protein
(GFAP)(Calbiochem, San Diego, CA) and rat monoclonal
anti mouse F4/80 was produced by our laboratory. Sec-
ondary antibodies used included FITC-coupled goat anti-
mouse, Cy5-coupled anti-rat and Cy5-coupled goat anti-
rabbit. Secondary antibodies were obtained from Jackson
Immuno-Research Laboratories Inc. (West Grove, PA).
Propidium iodide (PI) was obtained from Molecular
Probes (Eugene, OR).
Primary cortical cultures
Cortical cultures were prepared essentially as described
previously [3,29-31]. Cortices from E15 embryos (mouse
strain CD1, from Charles River Laboratories, Wilmington
MA) were removed and the cells were dissociated by diges-
tion with trypsin (0.025%) for 30 min at 37°C, followed
by physical dissociation resulting from pipeting the cells
(15–20 times) through a 5-ml pipette placed in a 15-ml
conical tube with a loose seal between the bottom of the
tube and the pipette. The cells were then plated at a den-
sity of 1.1 × 106 trypan blue-excluding cells per well in a
12-well plate (Corning dishes pre coated with poly-D-
lysine). Cells were initially plated in 1-ml of MEM with
Earle's salts supplemented with 5% horse serum (heat
inactivated), 5% fetal bovine serum (heat inactivated), 30
mM glucose, 2 mM glutamine and grown at 37°C in
humidified chambers with 5% CO2. The cultures were fed
the next day by replenishing about half the volume with
fresh growth media (MEM with Earle's salts supplemented
with 10% horse serum, 30 mM glucose, 2 mM glutamine)
and fed every 2–3 days after that to generate mixed corti-
cal cultures. After nine days in culture, these mixed cul-
tures were exposed to AraC (4–8 μM) for a 24 hour period
to limit the growth of mitotic cells. Each preparation of
AraC differed with respect to its anti-mitotic efficacy and
was tested for optimal inhibition of cell growth with min-
imal toxicity. These mixed culture preparations contained
approximately 30% of the cells as neurons [3]. All excito-
toxicity experiments with mixed cultures were started 2
days after the last feeding and were used 15 days after plat-
ing. At this stage, the neurons exhibited the most consist-
ent response to NMDA while still having low background
death. Neuronal-enriched cultures were prepared as above
except that, on the second day after plating, the cells were
treated with 2–4 μM AraC for a 24-hour period and fed
only once more with feeding media (MEM with Earle's
salts supplemented with 10% horse serum, 30 mM glu-
cose, 2 mM glutamine). Neuronal-enriched cultures
which were incubated for 8 days in vitro (DIV), contained
between 90–95% neurons as determined by immunoflu-
orescent microscopy as the number of PI stained nuclei
that were associated with cells labeled with the neuronal-
specific marker MAP-2 (data not shown). Excitotoxicity
experiments with these cultures were started after the cul-
tures were maintained for 8 DIV, a time at which there is
low background neuronal death and the neurons exhibit
a consistent response to NMDA stimulated excitotoxicity.
Excitotoxicity experiments were performed in growth
media that contained 10% horse serum unless stated oth-
erwise.
Cortical cultures were also examined in serum-free media.
Cortical cultures were prepared as described and allowed
to incubate in plating media (MEM with Earle's salts sup-
plemented with 5% horse serum, 5% fetal bovine serum,
30 mM glucose, 2 mM glutamine) for 24 hours. The
media was then replaced with neurobasal media contain-
ing 2% B27 supplement (Invitrogen) and, 24 hours later,
the cultures were then exposed to AraC (4–8 μM). The cul-
tures were fed 24 hours after this by replacing one half of
the media with fresh Neurobasal media with 2% B27 sup-
plement. These cultures were used in excitotoxicity exper-
iments 8 days after the initial plating.
Excitotoxicity assay
Excitotoxicity was measured using a modified protocol of
established methods as described in detail elsewhere
[3,29-31]. Neuronal cell death was assessed by photo-
graphing the same four fields in each well, before and
after addition of NMDA. Each field contained 150 to 300
neurons prior to treatment with NMDA. The numbers of
intact neurons were counted before NMDA treatment as
the phase bright cells (see Figure 1). Twenty hours after
treatment with NMDA (in the presence or absence of neu-
roprotective agents) one ml of trypan blue (0.4%) was
added to the media (final concentration of 0.2%) and the
volume of this mixture was adjusted to leave minimal
solution to cover the cells. The cells were incubated with
the trypan solution for 20 minutes. Plates were marked
with reference so that the same fields could be photo-
graphed as shown in Figure 1. Cells that did not stain with
trypan blue were counted as live cells. These trypan blue-
excluding cells also did not stain by the necrotic dead cell
stain ethidium homodimer (Molecular Probes), but did
stain with the live cell stain Calcein AM green (Molecular
Probes) (data not shown). All excitotoxicity experiments
were repeated at least three times. The percentages of sur-
viving neurons were determined in each field by dividing
the total of trypan-excluding cells after NMDA treatment
by the total number of cells in that field counted prior to
NMDA. A total of three fields were examined in each treat-
ment per plate. The average percent neuronal survival was
assessed for each treatment from at least three independ-
ent experiments and included the average from a mini-
mum of nine fields for each condition reported in each
figure. In mixed cultures, neurons were identifiable asJournal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
Page 4 of 16
(page number not for citation purposes)
phase-bright cells that were observed in a focal plane
above the glial monolayer. This was confirmed in sister
cultures by immunofluorescence showing that these cells
were stained with the neuronal marker MAP-2 [3,29-31].
The cell counting method for determining viable cells can
be used when cultures are grown in the presence of serum
(as in most of our current experiments) or when testing
agents that may have antioxidant properties which inter-
fere with assays that measure release of the enzyme lactate
dehydrogenase (LDH) into the media from dead cells. For
each experiment, the concentration of NMDA required to
give about 80% neuronal death was pre-determined and
varied between different lots of NMDA and cell prepara-
tions. Typical concentrations of NMDA required for 80%
neuronal death ranged between 10–40 μM for neuronal-
enriched cultures and 15–80 μM for mixed cultures. All
experiments were conducted using this high amount of
NMDA-induced neuronal death for convenience and reli-
ability in scoring the survival after NMDA treatment. For
neuroprotective experiments, the neuroprotective agent
(NS398, Ono 8711 or SC51089) was added directly to the
growth media coincident with the addition of NMDA. In
all cases, the effect of each neuroprotectant treatment (or
Excitotoxicity assay and neuroprotection by Ono 8711 Figure 1
Excitotoxicity assay and neuroprotection by Ono 8711. Fields of neuronal-enriched cultures were photographed 
before treatment with vehicle (A) or the EP1 receptor antagonist Ono 8711 (B). These cultures were then treated with 
NMDA (15 μM) and photographed twenty hours later after staining with trypan blue dead cell stain for vehicle (C) and Ono 
8711 (D). Examples of cells that survived NMDA treatment and excluded trypan blue are indicated by a black arrow in each 
panel. An example of a cell in each field that was killed by NMDA (as indicated by staining with trypan blue) is indicated by a 
green arrow. The numbers of neurons were counted for each of the cultures before and after NMDA (as non Trypan-stained 
cells). In this example, the addition of 30 nM Ono 8711 increased the percent of surviving neurons from 20% to 50%. Images 
were captured at 20 × magnification.Journal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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combination of treatments) on neuronal viability in the
absence of NMDA was also determined by photographing
the cells before and 20 hours after treatment with the
agent indicated. In each experiment, 500 to 2000 neurons
were counted for each treatment.
Microglial and astrocyte cultures
Microglial cultures were prepared according to the meth-
ods described [32]. Brains were removed from 1 day old
CD1 mice and the cerebral cortices were obtained. The
meninges were removed and the tissue was minced and
digested with trypsin (0.025%) for 30 min at 37°C, fol-
lowed by physical dissociation as described earlier for
neuronal cortical cultures. The cells were plated in MEM
containing 10% fetal bovine serum into 25 cm2 tissue cul-
ture flasks (1 brain per flask) that were pretreated with
poly-d-lysine. Cultures were grown for 7–9 days at 37°C
and the microglial cells were removed by shaking on an
orbital shaker at 250 rpm for 30 min. Microglial cells were
then centrifuged for 5 min at 1500 g and resuspended in
neurobasal medium with 2% B27 supplement and plated
onto either poly-D-lysine coated12-well plates or tran-
swells (12 mm diameter) at a density ranging from 1.5 ×
105 to 3 × 105 cells/mm2. Lower cell density microglial cul-
tures were more difficult to grow. After 8 days in culture,
microglial transwells were transferred onto 5 day old neu-
ronal-enriched cultures (in 12 well plates) and co-cul-
tured another 48 hours prior to the start of excitotoxicity
experiments. Microglial cultures contained greater than
95% microglial cells as determined by staining with
microglial markers, F4/80 or CD11b.
Astrocyte cultures were prepared as described [32]. Cells
were isolated from cerebral cortices from 1 day old mice
as described above and the cells were suspended in MEM
containing 10% fetal bovine serum and plated onto either
transwells or tissue cultures plates (1 × 105 cells/mm).
These cultures were grown at 37°C for about 1–2 weeks
until the cells reached confluency. Transwell astrocyte cul-
tures were transferred to neuronal-enriched cultures (5
day old cultures), 48 hours before the start of excitotoxic-
ity experiments.
Conditioned media experiments
Media was harvested from mixed cultures (15 DIV) and
neuronal-enriched cultures (8 DIV) and centrifuged for 5
minutes (1000 × g) to eliminate any residual cells. Freshly
harvested media was subsequently exchanged between
the mixed and neuronal-enriched culture preparations.
Since the neuronal-enriched cultures (8 DIV) did not sur-
vive a direct media exchange, the mixed conditioned
media was exchanged in the 12-well plates by seven two-
fold dilutions. Neuronal-enriched media was directly
exchanged on the mixed cultures (15 DIV) in one
exchange. Excitotoxicity experiments were performed as
described above.
Transwell experiments
Mixed cortical cultures, microglia or astrocytes were
plated onto the top side of the transwell inserts (0.4 μm
pore size polycarbonate membrane coated with poly-D-
lysine, Corning catalog number 3401, Corning, NY) at the
cell density as described above. The mixed cultures on
transwells were treated with AraC (on day 9) and fed as
described for mixed cultures. These mixed culture tran-
swells (15 DIV) were transferred to neuronal-enriched
cultures 48 hours prior to treatment with NMDA. Neuro-
nal-depleted mixed cultures were obtained by exposure of
the mixed cultures (11 DIV) to 25 μM NMDA for 48 hours
prior to transfer of the transwells to plates containing
fresh media and three exchanges of media to remove
NMDA. The transwell cultures were positioned approxi-
mately 2 mm above the neuronal-enriched cultures and
the cells grown on the transwells were separated from the
neuronal-enriched cultures by the permeable transwell
membrane. The neuronal-enriched cultures were photo-
graphed prior to addition of the transwells and treatment
with NMDA. The mixed culture transwells were then
returned to the same wells of the neuronal-enriched cul-
tures and subsequently treated with vehicle, SC51089,
and then NMDA at a concentration that yielded approxi-
mately 20% neuronal survival. All drugs were added to the
media below the transwells. After 24 hours, the mixed cul-
ture transwells were removed and the neuronal-enriched
cultures were stained with trypan blue, photographed and
scored for neuronal survival as described above. Viability
of the mixed cultures, microglia cultures and astrocyte
coultures on the transwells prior to NMDA treatment was
verified using dead cell stain ethidium homodimer and
the live cell stain Calcein AM green.
Statistical analyses
The data from the NMDA excitotoxicity experiments were
analyzed using InStat software (GraphPad software, San
Diego, CA). Data from each treatment group passed the
method of Kolmogorov and Smirnov for normal distribu-
tions making it appropriate for parametric tests to assess
significance between treatment groups. One way ANOVA
with post-test using the Tukey-Kramer multiple compari-
son tests was performed as to determine significance
between treatment groups at the confidence intervals indi-
cated. Pair-wise comparisons were performed using
unpaired students t-test.
Immunofluorescence assay
Cortical cultures were prepared for microscopy by first
rinsing the cultures with phosphate-buffered saline (PBS),
followed by fixing the cells with freshly prepared 2% para-
formaldehyde in PBS. Following five rinses with PBSJournal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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(minimum of 2 minutes per rinse), cells were permeabi-
lized with 0.2% triton-X 100 in PBS, rinsed (3 rinses with
PBS, minimum of 5 minutes per rinse) and blocked with
Image-it FX signal enhancer solution (Molecular Probes).
Primary antibodies were added at dilutions of (1:500) for
rabbit polyclonal antibody for EP1 (final concentration 1
μg/ml), (1:400) mouse monoclonal antibody for MAP-2
(final concentration 1 μg/ml), (1:500) rat monoclonal
GFAP (final concentration of 1 μg/ml), (1:100) rat poly-
clonal for F4/80 (final concentration 10 μg/ml) and
(1:100) rat monoclonal antibody for CD11b (final con-
centration 5 μg/ml). Incubation of the anti-EP1 antibod-
ies with the EP1 epitope blocking peptide (10:1 molar
ratio of peptide: antibody) (Cayman Chemical Company)
blocked binding (data not shown). Secondary antibodies
were diluted (1:400) for FITC-conjugated anti-mouse
(IgG, H&L) (final concentration 3 μg/ml), (1:400) FITC-
conjugated anti-rat (final concentration 3 μg/ml), and
(1:800) Cy5-conjugated anti-rabbit (IgG, H&L) (final
concentration 1.5 μg/ml). The fluorochrome-conjugated
antibodies were cross-adsorbed to immunoglobulins
from other species to ensure specific multiple labeling. All
antibodies were diluted in PBS with 0.025% Tween 20.
Combinations of the selective primary antibodies were
added to the sections and incubated overnight in a
humidified chamber at 4°C. Conjugated secondary anti-
bodies were added for 1 hour at room temperature (RT)
followed by staining with PI to visualize cell nuclei. PBS
washes were done (3 rinses with PBS, minimum of 5 min-
utes per rinse) between measures prior to mounting. Sec-
tions were mounted with ProLong Gold anti-fade
permanent mounting media (Molecular Probes). To
account for any background non-specific staining, nega-
tive controls with normal mouse and normal rabbit serum
at concentrations comparable to primary antibodies were
conducted in parallel.
Confocal laser scanning microscopy
Personal Confocal Microscope PCM-2000 (NIKON,
Melville, NY) with Argon, HeNe green and HeNe red
lasers were used to acquire the images. Simple Personal
Confocal Image program (Simple PCI, Compix, Cran-
berry Township, PA) was used to acquire digital images
and construct compilations. The fluorochromes were
resolved into three different image channels with respec-
tive emission filters. The FITC label was detected with the
Argon laser at 488 nm, Cy5 with the red HeNe laser at 633
nm and PI was visualized with the green HeNe laser at
605/32 nm narrow band pass width filter. The stained cul-
tures were individually scanned for each respective fluor-
ochrome and the multi-focal program (z-focus) was used
to create a stereopsis image. The three separate images
were merged together to acquire the final triple-colored
image; the PI image was converted to blue color during
merge. This allowed for comprehensive visualization of
labeling throughout the entire depth of the sample.
Images were stored as digital files and the final figures
were created using Photoshop (Adobe, San Jose, CA). The
total magnification of each image presented is equal to
(magnification of the objective) × (width of the image
panel in cm) × (0.93). This scale of image size was based
on size calibration using an American Optical improved
Neubauer hemacytometer and simple PCI linear calibra-
tion scales.
Quantification of neuronal nuclear EP1 expression in 
different culture preparations
The amount of neuronal expression in the nucleus was
quantified from digital images of immunofluorescence
confocal microscopy of cortical cultures stained with PI
(for nuclei) and immuno-stained for EP1, and MAP-2.
Each image was captured with the same sensitivity settings
on the confocal microscope and all images were captured
with a 60× objective with 640 × 480 pixels. A blinded
observer (unaware of the culture preparation) counted the
number of pixels over the nuclear regions of the neurons
that were stained for EP1 with an enlarged image with
Adobe Photoshop. Each culture preparation was exam-
ined in four independent fields and the number of neu-
rons analyzed varied from 50–70 for each culture
preparation.
Prostaglandin measurements
PGE2 was measured using a prostaglandin enzyme-linked
immunosorbent assay (ELISA) detection kit (Cayman
Chemical Company) that uses a PGE2-specific antibody.
For both the mixed cultures (15 DIV) and neuronal-
enriched cultures (8 DIV), the media was exchanged from
the standard growth media (MEM with Earle's salts/10%
horse serum, 30 mM glucose, 2 mM glutamine) to HBSS+
(Mg2+-free Hanks buffered salt solution, 3 mM CaCl2, 20
mM HEPES (pH 7.55), 13.4 mM NaHCO3, 30 mM glu-
cose and 25 μM glycine). Since the neuronal-enriched cul-
tures did not survive a direct media exchange, the media
was exchanged in the 12-well plates by seven two-fold
dilutions (repeated series of addition of 1 ml of HBSS+ to
1 ml of media, followed by removal of 1 ml). This resulted
in 0.78% of the original growth media remaining which
had no detectable amounts of PGE2. After the media was
exchanged, the cultures were exposed to a treatment of
NMDA that yielded < 10% neuronal death over the 90
min of the experiment. The mixed cultures were treated
with 100 μM NMDA for 15 min followed by treatment
with 3 μM of the NMDA antagonist MK801. The neuro-
nal-enriched cultures were treated with 200 μM NMDA
for 20 min, followed by treatment with 3 μM MK801. The
media was removed from the cultures 90 minutes after the
initial NMDA treatment and immediately frozen (-80°C)
for analyses at a later time. The amount of PGE2 in the
media was determined by enzyme immunoassay as perJournal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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the instructions from the manufacturer. This assay can
detect as little as 8 pg/ml of PGE2.
Results
Neuroprotection by an EP1 receptor antagonist
The neuroprotective effect of the EP1 receptor antagonist
Ono 8711 was examined using the assay for excitotoxicity
shown in Figure 1. The same field of the neuronal culture
was photographed before treatments, and twenty hours
after continuous exposure with NMDA. In this assay the
fate of each neuron can then be followed over time. In Fig-
ure 1A, the neuronal-enriched cultures were treated with a
concentration of NMDA that leaves only about 20% of the
neurons viable as determined by trypan blue exclusion
(Figure 1C). However, when 30 nM Ono 8711 was added
to a sister culture prior to treatment with the same concen-
tration of NMDA, there was a dramatic increase in the
number of surviving neurons (Figure 1B and 1D). A more
extensive analysis using this assay was performed with
treatments of Ono 8711 at concentrations of 0.3 nM, 1
nM, 3 nM, 10 nM, 30 nM and 100 nM added just prior to
treatment with NMDA. As seen in Figure 2, treatment with
as little as 3 nM of Ono 8711 increased the percent of sur-
viving neurons to nearly 60%, compared with 20% as
seen with NMDA alone. Similar amounts of neuroprotec-
tion were observed with treatments of 10 nM and 30 nM
Ono 8711 and were not significantly different than treat-
ments with 30 μM of the COX-2 inhibitor NS398. This
concentration of NS398 is the optimal concentration for
protection with this drug [2,3]. However, the highest con-
centration of Ono 8711 tested (100 nM) yielded no signif-
icant neuroprotection and resulted in significantly lower
amounts of surviving neurons than observed with 3, 10
and 30 nM Ono 8711. Treatment of cultures with 100 nM
Ono 8711 in the absence of NMDA did not result in any
detectable toxicity of neurons (data not shown). Another
EP1 receptor antagonist, SC51809 [28] at a concentration
of 10 μM, produced the same amount of neuroprotection
in neuronal-enriched cultures as seen with Ono 8711 and
30 μM NS398 (Figure 2).
Neuroprotection by EP1 antagonists is sensitive to 
modulation by non-neuronal cells
In the preceding experiments, the neuroprotective effects
of Ono 8711 and SC51089 were assessed using neuronal-
enriched cultures where neurons account for about 90–
95% of the cells in the culture (see methods). Neuropro-
tection mediated by the EP1 antagonists in these neuro-
nal-enriched cultures, is consistent with EP1 antagonists
directly blocking EP1 receptor activation on neurons. In
order to assess whether this effect is modulated by other
cell types, we examined whether EP1 receptor antagonists
were neuroprotective in a mixed culture preparation,
where approximately 30% of the cells present in the cul-
ture were neurons (see methods). In sharp contrast to the
results obtained with neuronal-enriched cultures, there
was no appreciable neuroprotective effect elicited by treat-
ment with any concentration of the EP1 antagonist Ono
8711, 10 μM SC51089 or with 30 μM NS398 (see Figure
3). A similar lack of neuroprotection by the EP1 antago-
nists was also observed when neuronal-enriched cultures
were prepared with insufficient amounts of the anti-
Neuroprotection by EP1 receptor antagonists and a COX-2  inhibitor in neuronal-enriched cultures Figure 2
Neuroprotection by EP1 receptor antagonists and a 
COX-2 inhibitor in neuronal-enriched cultures. The 
effect of varying concentrations of Ono 8711 on neuronal 
survival to NMDA treatment was assessed using the assay 
outlined in Figure 1 (see methods). Cultures were either pre-
treated with the drug vehicle DMSO (veh), or the concentra-
tion of the drug indicated below each bar. The cultures were 
then treated with a concentration of NMDA that leaves only 
about 20% survival in the non-drug treated cultures (average 
[NMDA] = 15 μM). The percent survival for the treatments 
indicated was determined and plotted as percent surviving 
neurons. The shaded region of the bar graph shows the sur-
vival obtained with NMDA alone and the unshaded portion 
of the bar indicates the additional neuronal survival resulting 
from co-treatment with the drug indicated. In each experi-
ment, the neuronal cell numbers were counted from four 
fields (similar to that shown in Figure 1) from each treatment 
and averaged. The results shown were then average from at 
least four independent experiments. (* indicates P < 0.05 and 
** indicates P < 0.01 in comparison to vehicle treatment, # 
indicates a < 0.05 in comparison to the concentrations (3,10 
and 30 nM) of Ono 8711, by ANOVA, Tukey-Kramer multi-
ple comparison test). The 100 nM Ono 8711 was not signifi-
cantly different from the vehicle control. Error bars are 
standard error of the mean (SEM).Journal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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mitotic agent AraC (see methods) to limit the growth of
non-neuronal cells (data not shown).
Media exchange between cultures
To assess whether the difference in response to the EP1
antagonists was due to differences in cell-derived compo-
nents in the culture media, experiments were done where
the media was exchanged between the two cultures. As
seen in Figure 4, EP1 antagonist SC51089 was still neuro-
protective in the neuronal-enriched cultures with media
transferred from mixed cultures. Conversely, SC51089
still did not confer neuroprotection in mixed cultures con-
taining media from neuronal-enriched cultures. There-
fore, the neuroprotective response to SC51089 remained
the same, irrespective to the source of media. These results
illustrate that the cellular environment in the mixed cul-
tures is important to determine whether the EP1 antago-
nist is neuroprotective. Alternatively, components in the
media from the mixed cell cultures are labile and lose
activity during the media transfer procedure or require
longer exposure time to elicit an effect.
Cellular composition of mixed and neuronal-enriched 
cultures
Cellular composition in both mixed and neuronal-
enriched cultures was examined by confocal immunoflu-
orescence microscopy to identify possible candidate non-
neuronal cell types that influence EP1 neuronal response.
Mixed cultures contained an abundance of cells stained
with the astrocyte-specific marker GFAP (Figure 5a) in
contrast to the neuronal-enriched cultures which con-
tained a rare GFAP-positive cell (Figure 5b). Microglia
were also present in the mixed cultures as indicated by the
presence of cells that contain the monocyte/macrophage
lineage marker, F4/80 (Figure 5c). F4/80 positive cells
were not detected in the neuronal-enriched cultures (Fig-
ure 5d). Similar results were obtained with the microglial
marker, CD11b (not shown). These results identify both
astrocytes and microglia as potential cell types in mixed
Lack of neuroprotection by EP1 receptor antagonists or  NS398 in mixed cultures Figure 3
Lack of neuroprotection by EP1 receptor antagonists 
or NS398 in mixed cultures. Ono 8711, SC51089 and 
NS398 did not confer neuroprotection in mixed cultures. 
Mixed cortical cultures were treated with the concentrations 
of Ono 8711 indicated, 10 μM SC51089 or 30 μM NS398 fol-
lowed by treatment with NMDA (average [NMDA] = 20 
μM). These cultures were treated in parallel with the neuro-
nal-enriched cultures shown in Figure 2. Neuroprotection 
was not observed with any concentration of Ono 8711, 
SC51089, or NS398. The results shown were the average 
(+SEM) from four independent experiments.
Neuroprotection following media exchange between mixed  and neuronal-enriched cultures Figure 4
Neuroprotection following media exchange between 
mixed and neuronal-enriched cultures. Media from 
mixed and neuronal-enriched (NE) cultures was exchanged 
(see methods) prior to challenge with NMDA (average 
[NMDA] = 15 μM for NE cultures and 20 μM for mixed cul-
tures) in the presence or absence of the EP1 antagonist 
SC51089 (shown as SC). The source of the media is shown 
above the bars and the culture below the bars. This is the 
average of four independent experiments. The protection by 
SC in the neuronal-enriched cultures with mixed media was 
significant (P < 0.01) by ANOVA, Tukey-Kramer multiple 
comparison test. The results shown were then averaged 
from four independent experiments.Journal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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cultures that could negate the neuroprotective effects of
EP1 antagonists.
Transwell co-cultures with neuronal-enriched cultures
In order to assess which of these different cell types could
affect neuroprotection by an EP1 antagonist, a series of
experiments were performed where different types of cul-
tures were grown on permeable transwell filters and
placed above neuronal-enriched cultures. When tran-
swells containing mixed cultures were placed above the
neuronal-enriched cultures (during and 48 hours prior to
NMDA challenge), the EP1 antagonist was not neuropro-
tective in the neuronal-enriched cultures grown below
(Figure 6). This experimental system with the mixed cul-
ture transwells now made the neurons in the neuronal-
enriched cultures respond similarly to EP1 antagonist as
the neurons contained in the mixed cultures (Figure 3).
This illustrates that soluble factors from the mixed cul-
tures influenced how the neurons in the neuronal-
enriched cultures responded to EP1 antagonists. Mixed
Cellular composition of mixed and neuronal-enriched cultures Figure 5
Cellular composition of mixed and neuronal-enriched cultures. Confocal immunofluorescence microscopy was per-
formed on mixed and neuronal-enriched cultures that were stained with neuronal specific antibody MAP-2 (green) and either 
the astrocyte-specific marker GFAP (red) (A and B) or the microglia marker F4/80 (red) (C and D), nuclei were stained with PI 
and appear blue. Prominent GFAP staining in mixed cultures is indicated with an arrow (A) and the rare astrocyte in the neu-
ronal-enriched culture is shown with an arrow (B). Microglia were prominent in mixed cultures (C) and two examples were 
marked with an arrow. Microglial staining could not be detected in the neuronal-enriched cultures (D). Images were captured 
at 10× magnification for A and B, 60× for C and 40× for D. Magnification bars are 100 μm for A and B, 20 μm for C and D.Journal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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cultures devoid of neurons also produced the same effect
when placed on transwells above neuronal-enriched cul-
tures rendering the neurons in the neuronal-enriched cul-
tures insensitive to the neuroprotective effects of the EP1
antagonist (Figure 6). This suggests that non neuronal
cells in the mixed cultures were negating the neuroprotec-
tive effect of the EP1 antagonist.
The effects of astrocytes and microglia were then individ-
ually examined for their potential influence on the neuro-
protective effect of the EP1 antagonist. Astrocyte transwell
cultures appeared to have little effect on the neuroprotec-
tion conferred by SC51089. However, when cultures of
microglia (90% of the cells were positive for the micro-
glial marker, F4/80) grown on transwells were placed
above the neuronal-enriched cultures, SC51089 was not
neuroprotective (Figure 6). These same trends for the dif-
ferent combinations of transwell cultures on neuronal-
enriched cultures were seen at two different levels of
NMDA-induced excitotoxicity (20% survival, Figure 6a
and 10% survival, Figure, 6b). None of the transwell cul-
tures were toxic to the neurons in the neuronal-enriched
cultures in the absence of NMDA (data not shown).
Therefore, these experiments showed that the presence of
microglia blocks neuroprotection by an EP1 antagonist.
The same effects of microglia on neuroprotection by an
EP1 antagonist was also observed in cultures grown in
defined serum-free media (see methods). In these cul-
tures, microglial transwells also abrogated the neuropro-
tective effects of SC51089 on neuronal-enriched cultures
(data not shown). This indicates that the effect of micro-
glia on neuroprotection by an EP1 antagonist was not due
to serum-derived components in the growth media.
Effects of microglia on sensitivity to NMDA-induced 
excitotoxicity
In the preceding experiments, the relative neuroprotective
effects of the EP1 antagonists with and without microglia
were compared under conditions where NMDA was
adjusted to produce equivalent amounts of neuronal
death in each culture condition. However, when microglia
were present in transwells above the neuronal-enriched
Effects of transwell co-cultures on EP1 antagonist-mediated neuroprotection Figure 6
Effects of transwell co-cultures on EP1 antagonist-mediated neuroprotection. Transwells containing either mixed 
cultures, neuron-depleted mixed cultures, astrocytes or microglia cultures were co-cultured with neuronal-enriched cultures 
for 48 hours prior to treatment with vehicle (veh) or the EP1 antagonist SC51089 (SC) and subsequent challenge with NMDA 
(average [NMDA] = 15 μM for neuronal-enriched cultures and astrocyte-containing cultures and 16 μM for cultures with tran-
swells containing mixed cultures, neuron-depleated mixed cultures and microglia). Neuronal viability was assessed 20 hours 
after NMDA in each culture paradigm (as outlined in Figure 1) and compared to neuronal-enriched cultures without transwells 
(first two bars in each set). The composition of the transwell cultures are marked above the bars. The relative amount of neu-
roprotection was assessed with two different amounts of NMDA-induced excitotoxicity 20% survival (A) and 10% survival for 
(B). For 10% survival the average [NMDA] = 12 μM for neuronal-enriched cultures and astrocyte-containing cultures and 18 
μM for cultures with transwells containing mixed cultures, neuron-depleated mixed cultures and microglia. Each set is the aver-
age (+ SEM) of four independent experiments. Protection by SC in neuronal-enriched cultures with and without astrocytes was 
highly significant (P < 0.001 by ANOVA Tukey-Kramer multiple comparison test). A line is included in the bar to show the 
additional amount of survival conferred by addition of the EP1 antagonist.Journal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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cultures, the neurons were more resistant to NMDA-medi-
ated excitotoxicity as indicated in the concentration-
response curves shown in Figure 7. Therefore, in this con-
text, microglia conferred a neuroprotective effect on the
cultures. However, despite this neuroprotective effect elic-
ited by microglia, EP1 antagonists lacked any additional
neuroprotective effect in cultures containing microglia.
Microglia alter neuronal response to EP1 antagonists
The preceding experiments demonstrated that the pres-
ence of microglia in the culture alter how the EP1 receptor
antagonists confer neuroprotection following an excito-
toxic challenge with NMDA. However, those experiments
do not distinguish whether these differences are due to
microglial-induced changes in neuronal EP1 response or
are an indirect consequence of EP1 signaling in the micro-
glia. In order to test whether microglia can induce changes
in neuronal response to EP1 antagonists, neuronal-
enriched cultures were co-cultured with microglial tran-
swells for 48 hours, then the microglial transwells were
removed prior to challenge with NMDA. As seen in Figure
8, this pre-incubation with microglia was sufficient to
abolish the neuroprotective affect of the EP1 antagonist in
the neuronal-enriched cultures. Notably, the microglial
preconditioned neuronal-enriched cultures were also
more resistant to NMDA similar to that seen when micro-
glia are present during the excitotoxic challenge (data not
shown). Since microglia need not be present during the
Microglial influence on NMDA-induced neuronal death Figure 7
Microglial influence on NMDA-induced neuronal death. Neuronal-enriched cultures were incubated with or without 
microglial transwell cultures for 48 hours and were exposed to varying concentrations of NMDA. Neuronal death was 
assessed as depicted in Figure 1 after 20 hours of continuous NMDA exposure. The results are the average of two independ-
ent experiments. Error bars for each concentration of NMDA represent the SEM.Journal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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challenge with NMDA to alter the neuroprotective effects
of EP1 antagonist, this would suggest that microglia are
able to alter the EP1 response in neurons. The potential
effect of microglia on EP1 expression and NMDA induced
PGE2 production was subsequently examined.
Neuronal expression of EP1 in mixed cultures and 
neuronal-enriched cultures with and without microglial 
transwells
EP1 receptor antagonists may have diverse neuroprotec-
tive properties with different culture preparations because
of potential microglial-induced changes in neuronal EP1
receptor expression. In order to address this possibility,
the neuronal expression of EP1 receptor was examined by
immunofluorescence confocal microcopy for mixed cul-
tures and neuronal-enriched cultures in the presence or
absence of microglial transwells. As seen in Figure 9, there
was no appreciable net reduction in the amount of EP1
receptor expressed in microglia-containing cultures. How-
ever, there was a significant, two-fold decrease of EP1
expression in the nucleus in the neuronal-enriched cul-
tures containing microglial transwells (Figure 9b) and in
the mixed cultures (Figure 9c) compared to neuronal-
enriched cultures (Figure 9a). Therefore, higher amounts
of nuclear EP1 were seen in the cultures in which EP1
antagonists were neuroprotective.
NMDA stimulation of PGE2 in mixed and neuronal-
enriched cultures
We have shown previously that NMDA stimulates the syn-
thesis and release of PGE2 in cortical cultures [3,14]. A
comparison of the NMDA-stimulated release of PGE2 by
neuronal-enriched and mixed cultures was done to assess
whether differences in neuroprotection by COX-2 inhibi-
tors and EP1 receptor antagonists could be due to changes
in PGE2 production. Both culture preparations showed
about a six to nine-fold increase in PGE2, 90 minutes after
treatment with NMDA (Figure 10A and 10B) and this
induction was blocked by the NMDA receptor antagonist
MK801 (3 μM) (data not shown). The net amount of
PGE2 in the mixed cultures was about five-fold higher
than in the neuronal-enriched cultures. In both cases the
concentration of NMDA-induced PGE2 (425 pM for mix
and 85 pM for neuronal-enriched cultures) was below the
Ki reported for the EP1 receptor of 22 nM [33]. However,
as noted previously [14], the concentration of PGE2 in the
media may not reflect higher local concentrations at the
site of synthesis near the neurons. These findings indicate
that a lack of neuroprotection with the EP1 antagonists in
cultures containing microglia was not due to an inability
to synthesize PGE2.
Discussion
In this study we found that two structurally distinct EP1
receptor antagonists (Ono 8711 and SC51089) protect a
significant percentage of neurons against a sustained
exposure to NMDA in primary neuronal cultures devoid
of microglia. The neuroprotective effect of these agents is
mediated by specifically blocking the EP1 receptor since
maximal neuroprotection with Ono 8711 occurred with
concentrations as low at 3 nM, which is just above the Ki
for the EP1 receptor (1.7 nM), (Watanabe et al., 1999).
Concentrations of Ono 8711 greater than 100 nM were
not directly toxic to neurons, but had no significant neu-
roprotective effect agonist NMDA-mediated toxicity. It is
not known what accounts for this effect, but higher con-
centrations of Ono 8711 may have off target actions
which may alter the contribution of EP1 to neuronal via-
bility or neuronal sensitivity to excitotoxic stimuli.
The pharmacological evidence that we demonstrated with
EP1 receptor antagonists is consistent with recent in vitro
[21,22] and in vivo studies demonstrating that EP1 activa-
tion contributes to neuronal death [23,24]. The role that
Microglial influence on EP1 antagonist-mediated neuropro- tection Figure 8
Microglial influence on EP1 antagonist-mediated neu-
roprotection. Neuronal-enriched cultures were cultured in 
the absence or presence of microglia-containing transwells 
for 48 hours after which the microglial transwells were 
removed (pre-conditioning with microglia). The cultures 
were then treated with NMDA (average [NMDA] = 25 μM 
for neuronal-enriched cultures and 100 μM for microglia pre-
conditioned media) in the presence or absence of the EP1 
antagonist SC51089 (10 μM) and scored for neuronal sur-
vival 20 hours later. Neuroprotection is only seen in the neu-
ronal-enriched cultures not exposed to microglia (P < 0.001 
ANOVA Tukey-Kramer multiple comparisons test). A line is 
included in the bar to show the additional amount of survival 
conferred by addition of the EP1 antagonist. These results 
show that preconditioning with microglia for 48 hours prior 
to NMDA treatment is sufficient to inhibit the neuroprotec-
tive effect of the EP1 antagonist. This is the average of three 
independent experiments.Journal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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neuronal EP1 activation plays in augmentation of neuro-
nal excitotoxicity is now beginning to be elucidated. EP1
is a G-protein coupled receptor linked to the inositol tri-
phosphate (IP3) signaling cascade and causes release of
intracellular calcium [34]. Recent studies by Iadecola and
colleagues demonstrate that EP1 activation impairs the
Na+-Ca2+ exchanger (NCX) leading to dysregulation of
intracellular calcium following NMDA receptor stimula-
tion [23]. The resulting increase in intracellular cytoplas-
mic calcium concentration is an integral component to
excitotoxic death and contributes to neuronal death
[35,36]. Another recent study indicated that EP1 activa-
tion can also contribute to excitotoxic death through the
AKT/PKB (protein kinase B) signaling cascade [26].
NMDA-induced neuronal death is associated with
decreased AKT excitotoxic stimuli [37]. EP1 inhibitors
increase AKT activity by inactivating the inhibitor of AKT,
PTEN (phosphatase and tensin homologue deleted on
chromosome 10), and subsequently inhibiting transloca-
tion of the proapoptotic protein BAD [26]. Our finding
Neuronal expression of EP1 receptor in cultures with or without microglia Figure 9
Neuronal expression of EP1 receptor in cultures with or without microglia. Neuronal-enriched cultures (A), neuro-
nal-enriched cultures with microglia (B) and mixed cultures (C) were immunostained with antibodies against the neuronal-spe-
cific marker, MAP-2 (green), EP1 (red) and nuclei were stained with propidium iodide (PI) (blue) prior to confocal microscopy. 
Nuclei with different amounts of EP1 staining are indicated with arrows in each panel. All images were captured at 60× magni-
fication and the bar indicates 10 microns. The relative amounts (+SEM) of nuclear EP1 expression for neuronal-enriched (NE), 
NE + microglia, and mixed cultures was determined for 60–75 neurons for each condition (see methods) and plotted in panel 
D. The neuronal-enriched cultures lacking microglia had significantly higher amounts of nuclear EP1 expression (ANOVA 
Tukey-Kramer multiple comparison test).Journal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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that EP1 antagonists protected neurons in neuronal-
enriched cultures is also consistent with a mechanism in
which neuronal activation of EP1 leads to cell death.
Our results indicated that when microglia were present in
the cultures, the neuroprotective properties of EP1 antag-
onists were lost. Gendron et al. demonstrated that EP1
antagonists conferred neuroprotection against excitotox-
icity induced by oxygen-glucose-deprivation in mixed
neuronal cultures [22]. However, they did not character-
ize the cellular composition with respect to microglia. In
their culture system anti-mitotic agents were added to
their mixed cultures on day 4 after plating compared to
our mixed cultures in which the anti-mitotic agents were
added on day 9 (see methods). This difference may have
limited the amounts of microglia in their system.
In our culture system, the loss of neuroprotection with the
EP1 antagonist occurred when the microglia were either
cultured with the neurons (as in the mixed cultures) or
when the microglia were co-cultured in transwells above
the neuronal-enriched cultures. Co-culturing of neuronal-
enriched cultures with microglia for 48 hours was also suf-
ficient to alter the neuroprotective effects of EP1 antago-
nists. This indicates that the microglial cultures were able
to produce soluble factors that could diffuse through the
0.4 μm pores in the transwell membrane and influence
EP1 response in the neurons in the neuronal-enriched cul-
tures. Simple transfer of media from the mixed cultures to
the neuronal-enriched cultures could not abolish neuro-
protection. This indicates that the soluble component(s)
from the mixed cultures that were able to affect EP1
response in the transwell cultures are either labile, not
incubated for sufficient times before NMDA challenge or
are produced in the mixed cultures during NMDA stimu-
lation. Identification of these components produced by
microglia and how they modulate neuronal EP1 response
will require further investigation.
The mechanism by which microglia inhibit the neuropro-
tective effects of EP1 antagonists appeared to be more
complex than just downregulation of neuronal EP1
expression or decreased NMDA-induced synthesis of
PGE2. However, there was a significant difference in cellu-
lar distribution of EP1 to the nuclear region in neurons
from cultures that lacked microglia. Additional studies
will be required to determine whether this change in EP1
localization is important to EP1 signaling and the viability
of neurons following NMDA stimulation. Nuclear locali-
zation of EP1 has been observed in neurons and brain-
derived endothelial cells, where stimulation of EP1 recep-
tors can induce changes in nuclear calcium concentrations
and modulate gene expression of genes such as c-fos [38].
In our culture systems, neurons were more resistant to
NMDA induced excitotoxicity when microglia were
present. Decreased neuronal nuclear expression of EP1
was also observed in microglia-containing cultures. It is
possible that the neuroprotective effect of microglia could
be in part due to a redistribution of EP1 expression.
NMDA induces prostaglandin E2 production in mixed and neuronal-enriched cultures Figure 10
NMDA induces prostaglandin E2 production in mixed and neuronal-enriched cultures. Media from mixed (A) and 
neuronal-enriched (B) cultures were analyzed by ELISA for the presence of PGE2 from cultures either treated with NMDA or 
vehicle (control). The amount of PGE2 detected (pg/ml) is plotted for the average (+SEM) from 4 independent experiments. 
Note that the scales of PGE2 differ between preparations. (**indicates P = 0.01 in comparison to vehicle treatment by 
ANOVA, Tukey-Kramer multiple comparison test).Journal of Neuroinflammation 2009, 6:5 http://www.jneuroinflammation.com/content/6/1/5
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Our data support a role for microglia in altering the neu-
ronal EP1 response. However, we cannot rule out whether
EP1 signaling in microglia can alter neuronal viability.
Further studies will be needed to assess the role that EP1
signaling in microglia play in modulating neuronal viabil-
ity. EP1 receptors were abundantly expressed in microglia
in our cultures (data not shown) and could play some role
in the interaction with neurons.
This study identified a new role for microglia as an impor-
tant modulator of the neuroprotective properties of EP1
antagonists in vitro. If the same interactions were to occur
in vivo, this could have important consequences with
respect to microglial-mediated effects on neuronal viabil-
ity. In vivo, microglia migrate to the site of neuronal
injury and have been implicated to play a role in stroke
and neurodegenerative diseases such as Alzheimer's dis-
ease, Parkinson's disease, multiple sclerosis, and HIV-
dementia [39]. It is presently controversial whether micro-
glia play a harmful or beneficial role in neuronal death
[39-41]. The role played by microglia in neuronal death
may differ depending on the stimuli used to induce death,
the cellular milieu and the presence of various factors
along with the specific intracellular pathways that are acti-
vated [39].
There are two examples in vitro where microglia have
been shown to be detrimental towards neurotoxin-
induced neuronal death that is associated with COX-2. In
an in vitro model of Parkinson's disease, COX-2 inhibi-
tors showed a dramatically reduced level of neuroprotec-
tion towards dopaminergic neurons in cultures that lack
microglia following MPP+  (1-methyl-4-phenylpyridin-
ium)-induced death [42]. Microglia were shown to be the
major source of MPP+-induced production of PGE2 as well
as contribute to increasing neuronal COX-2 induction. In
another example, microglia are also required for lipopol-
ysaccharide (LPS) – induced neuronal death in culture
[43]. In this case, stimulation of the EP2 receptor on
microglia induced expression of COX-2 and iNOS which
were required for neuronal death. These examples differ
from our studies where microglia appeared to have neuro-
protective effects and diminished the contribution of neu-
ronal EP1 receptor activation to excitotoxic death.
In light of the recently identified complications of cardio-
vascular disease associated with COX-2 inhibitors
([25,44,45], it is important to identify new targets down-
stream of COX-2 that contribute to neuronal death [46].
Inhibition of EP1 represents an attractive alternative to
COX-2 inhibition for neuroprotective strategies that could
be used for treating stroke and other neurodegenerative
diseases [23,24,47,48].
Conclusion
This study demonstrates that microglia may limit the con-
tribution of EP1 receptor activation towards neuronal
excitotoxicity. Understanding how microglia could limit
the contribution of EP1 to neuronal excitotoxicity is not
only an important consideration for designing neuropro-
tective treatments with EP1 antagonists but may also gen-
erate new approaches in the treatment of
neurodegenerative disease.
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